Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
Active, not recruiting · Phase 2 · NCT05002777
Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)
At a glance
- Research payments reported, 2025
- $49,307
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 22
About the trial
- Sponsor
- Sanofi
- Tested
- rilzabrutinib (drug)
- Dates
- Started 2021-12-07; completion 2029-12-31
- Results posted
- Not yet
All participants will receive rilzabrutinib orally. The screening period is up to 28 days, followed by a treatment period of 24 weeks for Part A. Participants who complete Part A and are deemed eligible for Part B can continue in the Core Part B period followed by an Extended Part B period for up to 253 weeks. There will be a 7-day safety follow-up period after receiving the last dose of study medication either in Part A (for those not eligible for Part B or early terminated) or Part B. In addition, each participant will be asked to attend an EOT-Core Part B visit when the last participant completes 52 weeks in Core Part B. The Extended Part B period will last for up to 253 weeks. The stu…
From ClinicalTrials.gov, last updated 2026-06-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $49,307 in research payments for this study in 2025 (29 payments).
Products named: Wayrilz
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amitabha Mazumder, M.D. Hematology & Oncology · Downey, CA
- Sarah E. Tomassetti, M.D. Hematology & Oncology · Torrance, CA
- Catherine M. Broome, MD Hematology & Oncology · Washington, DC
- David J. Kuter, MD DPHIL Hematology · Boston, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farber Mass General Brigham Ca Care Inc $18,017
- Toi Clinical Research $17,869
- Georgetown University Office of Tech Commercialization $11,372
- $1,500
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical C $550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.